Shares of Suja Life tumbled 9% to $14.16 on June 10, erasing most of a sharp five-session rally that had lifted the stock from $12.88, as investors reconsidered whether a return to profitability can compensate for a top line that fell short of expectations. Suja Life Swings to Profit but Revenue Guidance Leaves Investors Asking: Is the Juice Worth the Squeeze?
Shares of Suja Life slid 9% to $14.16 on June 10, wiping out a rally that had pushed the stock up more than 20% over five sessions. The selloff came one day after the organic beverage maker posted its first earnings as a public company — a report that showed sharper profits but a revenue outlook that fell just short of Wall Street's hopes, raising questions about whether this month-old IPO can sustain its growth story.
The Numbers Look Good Until You Read the Fine Print
Q1 net sales rose 22.5% year-over-year to $107.1 million, net income hit $7.7 million (versus a loss of $800,000 a year earlier), and adjusted EBITDA — a measure of operating cash profit — jumped 66.3% to $25 million, reaching a 23.4% margin.
Q1 revenue of $107.06 million actually beat analyst estimates of $105.99 million. But the trouble is forward-looking: the company guided for full-year revenue of $367M–$371M against a consensus of $371.06M , signaling potential deceleration from Q1's pace — right as management flagged a "transition period" as a newly public company.
A Newly Public Company Still Carrying Heavy Debt
Suja's May IPO priced 8.9 million shares at $21.00 — the low end of its range — raising roughly $173.6 million.
A chunk of that went straight to paying down its term loan to $164.9 million. At $14.16, the stock trades roughly 33% below its IPO price, meaning every early public investor is underwater. The remaining debt load, plus an estimated $19 million in annual net interest expense , will eat into cash flow and limit spending on marketing and distribution.
Wall Street Remains Bullish — For Now
Five covering analysts rate the stock a "Strong Buy" with an average 12-month target of $24.25 — implying roughly 71% upside. Goldman Sachs, Jefferies, and Evercore have all initiated with optimistic ratings. But that consensus was set before investors saw management's cautious tone on the call.
Margins Are the Real Bright Spot, but Growth Has to Follow
Gross margin expanded to 50.5%, and the ratio of selling, general, and administrative costs to sales improved from 41.3% to 35.3%. That operational discipline is real. Yet for a company trading at roughly a price-to-sales ratio of about 1.1x , sustained top-line acceleration — not just margin improvement — is what will determine whether the stock claws back toward its IPO price or settles into a lower range. The next quarter will test whether "transition period" was honest framing or early excuse-making.